Sells biological reagents, protein-analysis instruments and diagnostic products to academic and industry researchers, pharmaceutical and biotechnology companies, and clinical laboratories.
10-K for FY2026, filed Aug 24, 2026Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (โBio-Techneโ, โweโ, โourโ, โusโ or the โCompanyโ)โฆView โ
We manage the business in two operating segments โ our Protein Sciences segment and our Diagnostics and Spatial Biology segment. OurโฆView โ
Our customers for this segment include researchers in academia and industry (chiefly pharmaceutical and biotech companies as well asโฆView โ
The Bio-Techne Diagnostic division consists of regulated products traditionally used as calibrators and controls in the clinical setting.โฆView โ
The customers for the Spatial Biology division include researchers in academia as well as investigators in pharmaceutical and biotechโฆView โ
Customers buy consumables and most instruments as shipped goods; service arrangements may be paid in advance, on completion or in both stages, and royalties follow sales.
10-K for FY2026, filed Aug 24, 2026Consumables revenues consist of specialized proteins, immunoassays, antibodies, reagents, blood chemistry and blood gas quality controlsโฆView โ
We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice"โฆView โ
Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days.โฆView โ
10-K for FY2026, filed Aug 24, 2026
FY2026 revenue by reportable segment โ$1.2B
10-K for FY2026, filed Aug 24, 2026
$1.2B โ| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Protein Sciences
Sold outright
10-K for FY2026, filed Aug 24, 2026 |
72%
FY2023: 74%
|
Protein Sciences, FY2026
$874.6M Sources
|
Sold outright |
|
Diagnostics and Spatial Biology
Sold outright
10-K for FY2026, filed Aug 24, 2026 |
28%
FY2023: 26%
|
Diagnostics and Spatial Biology, FY2026
$336.4M Sources
|
Sold outright |
Academic and industry researchers buy directly and through distributors; pharmaceutical and biotech customers also buy research and therapy-development products, while instrument makers purchase many diagnostic controls and reagents through OEM agreements.
10-K for FY2026, filed Aug 24, 2026Our customers for this segment include researchers in academia and industry (chiefly pharmaceutical and biotech companies as well asโฆView โ
The customers for the Spatial Biology division include researchers in academia as well as investigators in pharmaceutical and biotechโฆView โ
The Asuragen-branded products are sold primarily to laboratories for use in lab-developed tests or in kit form as regulated diagnosticโฆView โ
Yes. It kept 15 cents of every revenue dollar as net income in FY2026 and turned 22 cents into free cash flow.
10-Q/A, filed Nov 12, 2026
Open tableView โ
8-K, filed Sep 23, 2026
MINNEAPOLIS โ September 23, 2026 โ Bio-Techne Corporation (NASDAQ: TECH) (โBio-Techneโ), a global provider of life science tools, reagentsโฆView โ
Growing. Revenue grew 10% in 4 years, from $1.1B in FY2022 to $1.2B in FY2026, about 2% a year.
Exosome Diagnostics divestiture
The older report described the ExoDx and ExoTRU tests under Exosome Diagnostics; the latest report says Bio-Techne divested Exosome Diagnostics.
10-K for FY2023, filed Aug 23, 2023 10-K for FY2026, filed Aug 24, 2026The Molecular Diagnostics division markets and sells products and services under the Exosome Diagnostics and Asuragen brands. The ExosomeโฆView โ
In September 2025, the Company received MDxHealth SA (โMDxHealthโ) stock as part of our divestiture of Exosome Diagnostics. The fair valueโฆView โ
Loading...